Shionogi
Shionogi & Co., Ltd., commonly known as Shionogi, is a prominent pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, Shionogi has established itself as a leader in the pharmaceutical industry, focusing on research and development in areas such as infectious diseases, pain management, and central nervous system disorders. With a strong presence in Japan and expanding operations in North America and Europe, Shionogi is renowned for its innovative core products, including antiviral treatments and analgesics. The company’s commitment to advancing healthcare solutions has led to significant milestones, including the development of groundbreaking therapies that address unmet medical needs. Shionogi's dedication to quality and innovation has positioned it as a key player in the global pharmaceutical market, earning recognition for its contributions to public health and patient care.
DitchCarbon Score
How does Shionogi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shionogi's score of 65 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shionogi's reported carbon emissions
In 2023, Shionogi reported total carbon emissions of approximately 214,942,000 kg CO2e. This includes 40,373,000 kg CO2e from Scope 1 emissions, 31,650,000 kg CO2e from Scope 2 (market-based), and a significant 142,919,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its carbon footprint, aiming for a 46.2% reduction in Scope 1 and 2 emissions by 2030, based on 2019 levels. Additionally, Shionogi plans to cut Scope 3 emissions from purchased goods and services by 20% within the same timeframe. For Scope 2 emissions specifically, Shionogi has committed to a 30% reduction from 2020 levels by 2030. Looking further ahead, the company has pledged to achieve net-zero emissions across all scopes by 2050. These commitments align with industry standards for climate action and demonstrate Shionogi's dedication to sustainability in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 41,349,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 46,501,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shionogi is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
